Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliflapon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliflapon SCHEMBL1004174 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL29405516 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL8798993 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL30386644 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL2109295 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL2110833 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL7818529 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9123409 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9123415 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL7818344 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| CN-107929743-A | Treat the high penetrating power prodrugs composition and medical composition of pulmonary disease | 苏州泰飞尔医药有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-104540504-A | High penetration prodrug compositions and pharmaceutical compositions for treating pulmonary diseases | TECHFIELDS PHARMA CO LTD | 2015-04-22 | — | — | CN | claimed |
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | claimed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | claimed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | claimed |
| US-5646162-A | ATHEROSCLEROSIS TREATMENT | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-08 | — | — | US | claimed |
| EP-0666849-A4 | ARYL AND HETEROARYLMETHOXYPHENYL INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1995-12-13 | — | — | EP | claimed |
| EP-0666849-A1 | ARYL AND HETEROARYLMETHOXYPHENYL INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0637961-A4 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS. | MILES INC (US) | 1995-08-09 | — | — | EP | claimed |
| US-5391555-A | Administering 2-(4(2-quinolinyl-methoxy)-phenyl)-acetic acid derivatives; Crohn's disease | MILES INC. (US) | 1995-02-21 | — | — | US | claimed |
| EP-0637961-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | Bayer Corporation (US) | 1995-02-15 | — | — | EP | claimed |
| US-5358955-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1994-10-25 | — | — | US | claimed |
| WO-1994018976-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE WITH LEUKOTRIENE SYNTHESIS INHIBITORS | MILES INC. (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1994010148-A1 | ARYL AND HETEROARYLMETHOXYPHENYL INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-11 | — | — | WO | claimed |
| US-4970215-A | Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives and anti-allergic use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALOX5 302/4885HDAC6 2275/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALOX5 302/4885HDAC6 2275/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALOX5 302/4885HDAC6 2275/4885 |
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | ALOX5 110/4885HDAC6 339/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALOX5 302/4885HDAC6 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.